UK-based contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions was joined by Oxford/AstraZeneca COVID-19 vaccine co-inventor Professor Dame Sarah Gilbert, biotech industry representatives and local leaders to celebrate the official opening of a new 50,000 sqft development and GMP manufacturing facility in Nottingham.
In addition to Professor Dame Sarah Gilbert, the plaque-unveiling ceremony included local Member of Parliament, Darren Henry MP, and leading industry professionals.
Nikki Whitfield, CEO of Upperton Pharma Solutions, said: “This celebration marks another milestone in our growth journey as a business. We are looking forward to officially opening our doors to customers and offering a single site solution for development and GMP manufacturing.”
Prof. Dame Sarah Gilbert, Principal Investigator at the Pandemic Sciences Institute, University of Oxford commented: “During the pandemic we saw the importance of academia and industry working closely together to deliver life-saving vaccines and treatments. Upperton’s expansion into this new site is a great example of the crucial role UK-based pharmaceutical organisations have to play in addressing global health challenges. I look forward to collaborating with Upperton in the future.”
The new facility contains ten GMP manufacturing suites, cutting-edge quality control laboratories and formulation development capabilities equipped with a pilot plant.
The facility empowers Upperton to offer customers a transition from early formulation development to clinical trial supplies from Phase 1 to Phase 3, as well as niche scale commercial manufacturing.
The official opening marks another milestone for Upperton following the announcement and ongoing build of a new sterile facility on the same site, for the manufacturing of aseptic and terminally sterilised small volume liquids for parenteral, ocular and pulmonary delivery due for completion at the end of 2024.
